About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Rheumatoid Arthritis Clinical Trials in Chicago | 3,890 Studies | Clareo Health

Clinical Trials Rheumatoid ArthritisChicago

Rheumatoid Arthritis Clinical Trials in Chicago

Find 3,890 clinical trials for rheumatoid arthritis near Chicago, Illinois. Connect with research centers in your area.

All Rheumatoid Arthritis trials nationwide All trials in Chicago

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 1021-1040 of 3,890 trials

COMPLETEDPhase 22.2 miles

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

NCT01734512

This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.

Pediatric Recurrent Progressive Low-grade GliomasPediatric Progressive Low-grade Gliomas

University of California, San Francisco65 participantsStarted Dec 2012

Los Angeles, California, United States • Los Angeles, California, United States • Oakland, California, United States +15 more locations

Active Not Recruiting2.2 miles

OCS DCD Heart + CAP Continued Follow-Up

NCT05741723

The objective of this post-approval study is to evaluate long-term outcomes of patients enrolled in the OCS DCD Heart and OCS DCD Heart CAP studies.

Heart Transplant

TransMedics276 participantsStarted Nov 2019

La Jolla, California, United States • Palo Alto, California, United States • New Haven, Connecticut, United States +17 more locations

Rheumatoid Arthritis Trials in Other Cities

New York Los Angeles Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

Enrolling By InvitationNA2.2 miles

Neuronal and Network Mechanisms of Electrocortical Stimulation

NCT06391294

Electrocortical stimulation (ECS) mapping is a procedure used during brain surgeries, for example when treating diseases like epilepsy or when removing brain tumors. ECS mapping helps surgeons locate areas of the cerebral cortex (the outer part of the brain) that are important for everyday tasks like movement and speech. ECS mapping has been used for decades, and is considered the "gold-standard" tool for locating important areas of cortex. Despite this long history, there is still no clear understanding of exactly how ECS works. The goal of this study is to learn details about the effects ECS has on the brain. The main questions the study aims to answer are: 1) how ECS affects the neurons of the cortex at the stimulation site; and 2) how ECS impacts brain regions that are critically important for human speech and language. These so-called "critical sites" can be physically distant from one another on the brain's surface, requiring extensive ECS mapping and long surgeries. Critical sites are thought to be part of a speech/language network of brain areas, and so the study's goal is to learn about how they are connected. In some participants, the brain's surface will also be slightly cooled. This is a painless procedure that does not harm the brain's function, but could provide insight as to which parts of the brain (the surface, or deeper parts) are responsible for the effects of ECS. By improving the understanding of how ECS affects the brain and improving the ability to identify critical sites, this study could potentially lead to shorter surgeries and better outcomes for future individuals who need this care. Participants will be recruited from among individuals who are undergoing brain surgery for epilepsy treatment or tumor removal. Participants will complete simple tasks like reading words or naming pictures, similar to standard testing that is already performed during their hospital stay.

EpilepsyBrain Tumor Adult

Northwestern University65 participantsStarted May 2024

Chicago, Illinois, United States • Iowa City, Iowa, United States • Baltimore, Maryland, United States

Active Not RecruitingPhase 32.2 miles

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT00978458

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with or without temozolomide in treating patients with low-grade glioma. PURPOSE: This randomized phase III trial is studying radiation therapy so see how well it works when given together with or without temozolomide in treating patients with low-grade glioma.

Brain and Central Nervous System TumorsNeurotoxicity

Eastern Cooperative Oncology Group540 participantsStarted Nov 2009

Birmingham, Alabama, United States • Phoenix, Arizona, United States • La Jolla, California, United States +165 more locations

RECRUITING2.2 miles

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

NCT06274788

This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population

Parenteral Nutrition Associated Liver Disease (PNALD)Essential Fatty Acid DeficiencyMalnutrition+1 more

Fresenius Kabi40 participantsStarted Dec 2024

Fountain Valley, California, United States • Los Angeles, California, United States • Chicago, Illinois, United States +7 more locations

No Longer Available2.2 miles

Expanded Access Program for Revumenib

NCT05918913

This expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no approved treatment options.

Relapsed/Refractory Acute Leukemia

Syndax Pharmaceuticals

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Duarte, California, United States +32 more locations

COMPLETEDPhase 22.2 miles

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

NCT06848075

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.

Kallyope Inc.431 participantsStarted Mar 2025

Birmingham, Alabama, United States • Mobile, Alabama, United States • Tucson, Arizona, United States +63 more locations

RECRUITINGNA11 miles

The Impact of a Race-Based Stress Reduction Intervention

NCT05902741

The goal of this clinical trial is to learn whether a stress reduction program called Resilience, Stress, and Ethnicity (RiSE) improves well-being, inflammation, and the epigenome in African American (AA) women who have risk factors for heart or metabolic disease. The main question it aims to answer is whether an intervention that integrates cognitive-behavioral strategies focused on the impact that social stress, such as racism, has on the body, racial identity development, and empowerment. Participants will placed in one of the two following groups: * The RiSE program will focus on teaching participants how to reduce their stress levels and will meet online weekly for approximately 2 hours each week for 8 consecutive weeks. * The Health Education program will include education on how to improve general health and will meet online weekly for approximately 2 hours each week for 8 consecutive weeks. Participants will provide saliva to measure cytokines and DNA methylation (DNAm), complete questionnaires, and have blood pressure, heart rate, and weight measured at the following clinic visits: 1. Prior to starting the intervention 2. Mid-way through the intervention (Week 4) 3. End of the intervention (Week 8) 4. Six (6) months after the completion of the intervention

RacismStressInflammation

Loyola University300 participantsStarted Oct 2023

Maywood, Illinois, United States

COMPLETEDPhase 211 miles

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

NCT03499808

This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.

Amorphous, Eosinophilic, and Acellular DepositConstipationDiarrhea+10 more

SWOG Cancer Research Network43 participantsStarted Jun 2018

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +342 more locations

COMPLETEDPhase 1/272 miles

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT04491877

The primary objectives of the study were: * To assess the safety profile of each dose of the study product after each and any administration in all infants and toddlers regardless of baseline serostatus. * To characterize the Respiratory Syncytial Virus (RSV) A serum neutralizing antibody responses to the study product in each vaccine group after vaccination in RSV-naïve participants. The secondary objectives of the study were: * To quantify the amount of vaccine virus shed by each participant by baseline serostatus. * To determine the proportion of vaccinated infants and toddlers in each vaccine group infected with the vaccine virus at D56 (56 days after vaccination 1) for Cohorts 1, 2, 3 and 4, and at Day 84 (28 days after vaccination 2) for Cohorts 2 and 4 by baseline serostatus. * To characterize the RSV A serum neutralizing antibody responses to the study product in each vaccine group after vaccination in RSV-experienced participants. * To characterize serum RSV anti-F immunoglobulin G (IgG) antibody responses to the study product in each vaccine group after vaccination by baseline serostatus. * To characterize serum RSV antibody responses (RSV A-neutralizing and anti-RSV F IgG) to the study product in each vaccine group after the RSV surveillance season or at least 5 months after the last vaccine administration by baseline serostatus.

Respiratory Syncytial Virus Infection

Sanofi Pasteur, a Sanofi Company259 participantsStarted Sep 2020

Gardena, California, United States • La Mesa, California, United States • Los Angeles, California, United States +26 more locations

COMPLETEDNA165 miles

Cognitive Behavioural Therapy to Optimize Post-Operative Recovery Trial

NCT04274530

Psychological factors such as stress, distress, anxiety, depression, and poor coping strategies may be associated with ongoing pain following injuries such as fractures. To study this relationship, patients will undergo cognitive behavioural therapy (CBT) which is designed to modify such thoughts with the goal of reducing ongoing pain and improving quality of life. The goal of this study is to determine if CBT, versus usual care, reduces the prevalence of moderate to severe persistent post-surgical pain (PPSP) over 12-months post-fracture in patients with an open or closed fracture of the appendicular skeleton, treated with internal fixation.

Pain, PostoperativePain, AcutePain, Chronic+2 more

McMaster University1,024 participantsStarted Jan 2021

Indianapolis, Indiana, United States • Baltimore, Maryland, United States • Largo, Maryland, United States +7 more locations

Active Not RecruitingPhase 1/2201 miles

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.

Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)190 participantsStarted Jun 2017

Scottsdale, Arizona, United States • Los Angeles, California, United States • Denver, Colorado, United States +7 more locations

COMPLETEDPhase 4201 miles

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

NCT05207865

The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.

MigraineEpisodic MigrainePhonophobia+1 more

Pfizer441 participantsStarted Mar 2022

Phoenix, Arizona, United States • Hawthorne, California, United States • North Hollywood, California, United States +16 more locations

COMPLETEDPhase 1202 miles

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017

This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides\]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.

Minimal Residual DiseaseKRAS G12DKRAS G12R+9 more

Elicio Therapeutics25 participantsStarted Oct 2021

Duarte, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +7 more locations

Active Not Recruiting238 miles

Burden of Recreational Water Illness Due to Exposure to Cyanobacteria and Their Toxins in Freshwater Beaches in Canada

NCT06579170

Swimming and other recreational water activities at public beaches are increasingly popular leisure activities among Canadians. However, harmful algal blooms caused by blue-green algae (i.e., cyanobacteria) have also been increasing reported at Canadian public beaches in recent years. These algal blooms can cause various acute illnesses among recreational water users through ingestion, inhalation of aerosols, or skin contact with contaminated water. In addition, blue-green algae blooms and their toxins can cause illnesses in pets and wildlife. Currently, baseline data are lacking on the risk of recreational water illness from exposure to blue-green algae blooms in Canada. This study will identify the burden of recreational water illness among recreational water users at four targeted beach sites in Ontario, Manitoba and Nova Scotia, over a two-year period. A prospective cohort study design will be used. The investigators will determine the risk of acquiring acute illness outcomes in recreational water users, as well as their pet dogs, that engage in different levels of water contact at beaches at risk of blue-green algae blooms. The investigators will examine differences in illness risks by gender, age, and location. Relationships between cyanobacterial cell counts, toxin levels, and environmental conditions with the risk of acute illness among participants will be determined. Overall, results will provide important data on the risk of recreational water illness from exposure to blue-green algae and their toxins in Canadian beach settings.

GastroenteritisGastrointestinal DiseasesEye Infections+3 more

Toronto Metropolitan University2,500 participantsStarted Jun 2024

Winnipeg, Manitoba, Canada • Halifax, Nova Scotia, Canada • Port Perry, Ontario, Canada +1 more locations

TERMINATEDPhase 2251 miles

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT05019521

This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.

Geographic Atrophy

Alexion Pharmaceuticals, Inc.365 participantsStarted Aug 2021

Phoenix, Arizona, United States • Beverly Hills, California, United States • Encino, California, United States +125 more locations

TERMINATEDNA286 miles

A Multicenter Pragmatic Implementation Study of ECG-AI-Based Clinical Decision Support Software to Identify Low LVEF

NCT05867407

A prospective, cluster-randomized, care-as-usual controlled trial to evaluate the impact of an ECG-based artificial intelligence (ECG-AI) algorithm to detect low left ventricular ejection fraction (LVEF) on diagnosis rates of LVEF ≤ 40% in the outpatient setting. The objective of this study is to evaluate the impacts of an ECG-AI algorithm to detect low LVEF and an associated Medical Device Data System when used during routine outpatient care. The study will be conducted in 2 phases: feasibility assessment phase and clinical impact phase.

Ventricular Ejection Fraction

Anumana, Inc.11,610 participantsStarted Jun 2024

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States +2 more locations

Active Not Recruiting309 miles

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

NCT05673083

The goal of this pilot study is to evaluate the impact of All4Cure enrollment on patients with multiple myeloma. The main question it aims to answer are: • Does All4Cure effect patient activation as assessed by the PAM-13 survey? Participants will be asked to: * fill out quarterly PAM-13 surveys through the All4Cure website to assess patient activation. * fill out monthly Patient Reported Outcome (PRO) surveys through the All4Cure website. * fill out a baseline and exit All4Cure surveys through the All4Cure website to assess patient perceptions of All4Cure at the beginning and the end of the study.

Multiple Myeloma in RelapseMultiple MyelomaMultiple Myeloma, Refractory+1 more

All4Cure200 participantsStarted Mar 2023

Fayetteville, Arkansas, United States • Jacksonville, Florida, United States • Des Moines, Iowa, United States +4 more locations

COMPLETEDPhase 2412 miles

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

NCT04067011

This study is designed to evaluate the pharmacokinetic (PK) profiles of ciprofloxacin or doxycycline when administered orally, prior to, and following, the intramuscular (IM) administration of a two-dose schedule of AV7909 administered two weeks apart.

Emergent BioSolutions210 participantsStarted Aug 2019

DeLand, Florida, United States • Kansas City, Missouri, United States • Omaha, Nebraska, United States +1 more locations

COMPLETEDPhase 2479 miles

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

NCT05189210

The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for mild to moderate Alzheimer's disease (AD). Studies using in vivo and in vitro AD models have shown that GV1001 inhibits neurotoxicity, apoptosis, and the production of reactive oxygen species induced by amyloid beta (Aβ) in neural stem cells by mimicking the extra-telomeric functions of human telomerase reverse transcriptase (hTERT). In nonclinical studies, using both mild (early stage) and severe (late stage) AD mouse models, GV1001 was shown to improve cognitive function and memory, as well as significantly reduce the amount of Aβ and tau proteins. The multifunctional effect of GV1001 makes it a promising therapeutic option for the treatment for AD. In a completed Phase 2 study conducted in Korea, GV1001 showed significant improvement in change from baseline of Severe Impairment Battery score at Week 24 and demonstrated a clinically acceptable safety profile in patients with moderate to severe AD.

Mild to Moderate Alzheimer's Disease

GemVax & Kael199 participantsStarted Oct 2022

Adventura, Florida, United States • Greenacres City, Florida, United States • Miami, Florida, United States +32 more locations

PreviousPage 52 of 195Next

Other Conditions in Chicago

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia